Relationships of serum angiopoietin-like protein 4 and fibroblast growth factor 23 levels with severity and prognosis of patients with diabetes nephropathy

HU Lele; WEI Yinyu; WANG Jinyan; ZHU Kunliang; LIU Guoying

doi:10.7619/jcmp.20240358

Journal of Clinical Medicine in Practice > 2024 > 28(18): 56-61. > DOI: 10.7619/jcmp.20240358

HU Lele, WEI Yinyu, WANG Jinyan, ZHU Kunliang, LIU Guoying. Relationships of serum angiopoietin-like protein 4 and fibroblast growth factor 23 levels with severity and prognosis of patients with diabetes nephropathy[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 56-61. DOI: 10.7619/jcmp.20240358

Citation:

PDF (1100 KB)

Relationships of serum angiopoietin-like protein 4 and fibroblast growth factor 23 levels with severity and prognosis of patients with diabetes nephropathy

1.
Cangzhou Central Blood Station of Hebei Province, Cangzhou, Hebei, 061000
2.
Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, 061000
3.
Botou Hospital of Hebei Province, Cangzhou, Hebei, 062150

More Information

Received Date: January 18, 2024
Revised Date: July 16, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the relationships of serum angiopoietin-like protein 4 (ANGPTL4) and fibroblast growth factor-23 (FGF-23) levels with the severity and prognosis of patients with diabetic nephropathy.
Methods
A total of 120 patients (diabetic nephropathy group) with diabetic nephropathy were selected from July 2018 to July 2020 and divided into mild group (n=62) and severe group (n=58) according to the staging criteria of diabetic nephropathy; based on the prognosis within 3 years, they were also divided into good prognosis group (n=94) and poor prognosis group (n=26). Additionally, 102 diabetic patients were enrolled as diabetic group, and 81 healthy volunteers were selected as control group. The serum levels of ANGPTL4 and FGF-23 in diabetic nephropathy patients were detected by enzyme-linked immunosorbent assay (ELISA). Logistic regression analysis was used to analyze the influencing factors of prognosis, and receiver operating characteristic (ROC) curves were drawn to analyze the values of ANGPTL4, FGF-23 and their combination in assessing the severity and prognosis of diabetic nephropathy.
Results
The levels of ANGPTL4 and FGF-23 in the diabetic nephropathy group and simple diabetic group were significantly higher than those in the control group (P < 0.05); compared with the simple diabetic group, the levels of ANGPTL4 and FGF-23 in the diabetic nephropathy group were significantly increased (P < 0.05); the levels of ANGPTL4 and FGF-23 in the severe group were significantly higher than those in the mild group (P < 0.05); the ROC curve analysis revealed that the areas under the curve (AUCs) for assessing disease severity of ANGPTL4, FGF-23 and their combination were 0.748, 0.781 and 0.858 respectively, and the combined diagnosis was significantly better than FGF-23 (Z=2.149, P=0.032) and ANGPTL4 (Z=2.886, P=0.004) alone; the levels of ANGPTL4 and FGF-23 in the good prognosis group were significantly lower than those in the poor prognosis group (P < 0.05); significant differences were observed in diabetes duration, blood urea nitrogen (BUN), serum creatinine (Scr), fasting blood glucose (FBG), glycated hemoglobin (HbA1C), hypertension, ANGPTL4 and FGF-23 levels between diabetic nephropathy patients with different prognoses (P < 0.05); the Scr, ANGPTL4 and FGF-23 levels were all risk factors affecting the prognosis of diabetic nephropathy (P < 0.05); the ROC curve analysis for prognosis assessment showed that the AUCs of ANGPTL4, FGF-23 and their combination were 0.774, 0.795 and 0.874 respectively; the combined diagnosis was significantly better than FGF-23 (Z=2.385, P=0.171) and ANGPTL4 (Z=2.317, P=0.021) alone.
Conclusion
The serum levels of ANGPTL4 and FGF-23 are significantly increased in diabetic nephropathy patients, and they have certain reference value for the clinical diagnosis and prognosis assessment of diabetic nephropathy patients.
- diabetic nephropathy,
- angiopoietin-like protein 4,
- fibroblast growth factor-23,
- severity of disease,
- prognosis

FullText(HTML)

References (22)

References

[1]	TUTTLE K R, AGARWAL R, ALPERS C E, et al. Molecular mechanisms and therapeutic targets for diabetic kidney disease[J]. Kidney Int, 2022, 102(2): 248-260. doi: 10.1016/j.kint.2022.05.012
[2]	陈灵芝, 钟开义, 陈立国. 血清脂联素、分泌型黑色素瘤细胞黏附分子在2型糖尿病肾病中的表达及临床意义[J]. 实用临床医药杂志, 2023, 27(2): 13-16. doi: 10.7619/jcmp.20222051
[3]	ZHENG X, LIU R, ZHOU C C, et al. ANGPTL4-mediated promotion of glycolysis facilitates the colonization of Fusobacterium nucleatum in colorectal cancer[J]. Cancer Res, 2021, 81(24): 6157-6170. doi: 10.1158/0008-5472.CAN-21-2273
[4]	SHAWAF E A, ABU-FARHA M, DEVARAJAN S, et al. ANGPTL4: a predictive marker for diabetic nephropathy[J]. J Diabetes Res, 2019, 2019: 4943191.
[5]	MARTHI A, DONOVAN K, HAYNES R, et al. Fibroblast growth factor-23 and risks of cardiovascular and noncardiovascular diseases: a meta-analysis[J]. J Am Soc Nephrol, 2018, 29(7): 2015-2027. doi: 10.1681/ASN.2017121334
[6]	VÁZQUEZ-SÁNCHEZ S, POVEDA J, NAVARRO-GARCÍA J A, et al. An overview of FGF-23 as a novel candidate biomarker of cardiovascular risk[J]. Front Physiol, 2021, 12: 632260. doi: 10.3389/fphys.2021.632260
[7]	BERGMARK B A, UDELL J A, MORROW D A, et al. Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome: a secondary analysis of a randomized clinical trial[J]. JAMA Cardiol, 2018, 3(6): 473-480. doi: 10.1001/jamacardio.2018.0653
[8]	DOKUMACIOGLU E, ISKENDER H, MUSMUL A. Effect of hesperidin treatment on α-Klotho/FGF-23 pathway in rats with experimentally-induced diabetes[J]. Biomedecine Pharmacother, 2019, 109: 1206-1210. doi: 10.1016/j.biopha.2018.10.192
[9]	中华医学会内分泌学分会. 中国成人糖尿病肾脏病临床诊断的专家共识[J]. 中华内分泌代谢杂志, 2015, 31(5): 379-385.
[10]	杨辰华. 分期分型辨治糖尿病肾病体会[J]. 中医研究, 2017, 30(11): 45-47.
[11]	NAGIB A M, ELSAYED MATTER Y, GHEITH O A, et al. Diabetic nephropathy following posttransplant diabetes mellitus[J]. Exp Clin Transplant, 2019, 17(2): 138-146. doi: 10.6002/ect.2018.0157
[12]	LU Y F, LIU D W, FENG Q, et al. Diabetic nephropathy: perspective on extracellular vesicles[J]. Front Immunol, 2020, 11: 943. doi: 10.3389/fimmu.2020.00943
[13]	CHEN Y Q, POTTANAT T G, SIEGEL R W, et al. Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids[J]. J Lipid Res, 2020, 61(8): 1203-1220. doi: 10.1194/jlr.RA120000781
[14]	KOVROV O, KRISTENSEN K K, LARSSON E, et al. On the mechanism of angiopoietin-like protein 8 for control of lipoprotein lipase activity[J]. J Lipid Res, 2019, 60(4): 783-793. doi: 10.1194/jlr.M088807
[15]	ARYAL B, PRICE N L, SUAREZ Y, et al. ANGPTL4 in metabolic and cardiovascular disease[J]. Trends Mol Med, 2019, 25(8): 723-734. doi: 10.1016/j.molmed.2019.05.010
[16]	KERSTEN S. Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism[J]. J Lipid Res, 2021, 62: 100150. doi: 10.1016/j.jlr.2021.100150
[17]	FERNÁNDEZ-HERNANDO C, SUÁREZ Y. ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis[J]. Curr Opin Hematol, 2020, 27(3): 206-213.
[18]	BANO G, IMAM M T, BAJPAI R, et al. Expression of angiopoetin-like protein-4 and kidney injury molecule-1 as preliminary diagnostic markers for diabetes-related kidney disease: a single center-based cross-sectional study[J]. J Pers Med, 2023, 13(4): 577.
[19]	ZHOU R Y, GUO Q Y, XIAO Y, et al. Endocrine role of bone in the regulation of energy metabolism[J]. Bone Res, 2021, 9(1): 25.
[20]	MACE M L, OLGAARD K, LEWIN E. New aspects of the kidney in the regulation of fibroblast growth factor 23(FGF23) and mineral homeostasis[J]. Int J Mol Sci, 2020, 21(22): 8810.
[21]	LI Y X, GU Z H, WANG J, et al. The emerging role of bone-derived hormones in diabetes mellitus and diabetic kidney disease[J]. Front Endocrinol, 2022, 13: 938830.
[22]	COURBEBAISSE M, LANSKE B. Biology of fibroblast growth factor 23: from physiology to pathology[J]. Cold Spring Harb Perspect Med, 2018, 8(5): a031260.

[1]	DAI Xiaoyan, WANG Xinting, YUAN Xiaochen. Correlations of anxiety and depression with quality of life in patients with atrial fibrillation[J]. Journal of Clinical Medicine in Practice, 2022, 26(10): 54-57. DOI: 10.7619/jcmp.20214676
[2]	ZHOU Lili. Effect of refined nursing intervention on negative emotions and quality of life in maintenance hemodialysis patients[J]. Journal of Clinical Medicine in Practice, 2018, (14): 28-31. DOI: 10.7619/jcmp.201814008
[3]	LIU Li, TENG Lini. Influence of comprehensive nursing intervention on quality of life, negative emotion and cardiac function of patients with chronic cardiac failure[J]. Journal of Clinical Medicine in Practice, 2016, (20): 14-16,26. DOI: 10.7619/jcmp.201620005
[4]	YANG Min, XIE Juan, LIU Ailan, LI Lan. Effect of nursing intervention on improvement of negative emotions and life quality for patients with breast cancer[J]. Journal of Clinical Medicine in Practice, 2016, (14): 69-71. DOI: 10.7619/jcmp.201614022
[5]	WU Yanhua, YANG Yanhong. Effect of high quality nursing intervention on negative emotion and quality of life in elderly patients with chronic bronchitis[J]. Journal of Clinical Medicine in Practice, 2016, (12): 42-45. DOI: 10.7619/jcmp.201612014
[6]	LUO Hongdan. Effect of nursing intervention on negative emotion and quality of life in patients with sequelae of cerebral infarction[J]. Journal of Clinical Medicine in Practice, 2016, (8): 31-33. DOI: 10.7619/jcmp.201608010
[7]	ZHAO Yanhua. Influence of continuous nursing on postoperative negative emotions and quality of life in patients with bladder cancer after stoma of abdominal wall[J]. Journal of Clinical Medicine in Practice, 2016, (6): 64-66. DOI: 10.7619/jcmp.201606020
[8]	CHEN Yan. Effect of comprehensive nursing intervention on negative emotion and quality of life in elderly patients with chronic obstructive pulmonary disease in stable period[J]. Journal of Clinical Medicine in Practice, 2016, (6): 25-28. DOI: 10.7619/jcmp.201606009
[9]	YANG Xiaoping, CHEN Qinjie, LI Lina, CHEN Qing. Quality of life in infertile couples and its influencing factors[J]. Journal of Clinical Medicine in Practice, 2015, (10): 71-74. DOI: 10.7619/jcmp.201510022
[10]	XIANG Mei, LIU Aihua. The impact of high quality nursing on adverse emotion and quality of life in patients with colorectal cancer after operation[J]. Journal of Clinical Medicine in Practice, 2015, (6): 62-64. DOI: 10.7619/jcmp.201506020

Cited By

Cited by

Periodical cited type(13)

1.	刘倩. 难治性胃食管反流病的中医疗法研究近况. 湖北中医杂志. 2023(11): 63-66 .
2.	杨超，陈莉丽，杨振斌. 方晓华抑木扶土法临床运用验案举隅. 中国民间疗法. 2022(14): 105-108 .
3.	郭丽，夏军权，刘晓桐. 难治性胃食管反流病中医药诊治研究进展. 光明中医. 2021(22): 3790-3793 .
4.	贾军峰，李文萍. 和胃降逆饮联合西药及针刺治疗残胃引起的反流性食管炎的疗效及对血清胃动素的影响. 中国中西医结合消化杂志. 2020(12): 944-948 .
5.	刘妍. 疏肝降逆汤联合中医特色护理治疗胃食管反流病效果研究. 药品评价. 2019(01): 44-46 .
6.	马雪梅. 和胃降逆汤加减联合奥美拉唑、枸橼酸莫沙必利治疗肝胃郁热型胃食管反流病的临床观察. 中国民间疗法. 2019(05): 55-56 .
7.	房晓娜. 和胃降逆汤加减治疗胃食管反流病肝胃郁热型临床观察. 实用中医药杂志. 2019(04): 413-414 .
8.	邓粉会. 自拟和胃降逆汤辅助西药治疗胃食管反流病相关性支气管哮喘疗效观察. 人人健康. 2019(24): 114-115 .
9.	黄太伟. 半夏厚朴汤加减治疗难治性胃食管反流病的疗效研究. 实用医技杂志. 2018(06): 625-626 .
10.	高钟. 泮托拉唑、香砂养胃丸、左金丸联用治疗胃食管反流病的效果观察. 中国社区医师. 2018(19): 102-103 .
11.	姚向东. 雷贝拉唑、莫沙必利与玄麦甘桔三联用药治疗咽喉反流疾病的临床疗效. 中国合理用药探索. 2018(02): 8-11 .
12.	王巧凤，王胜业. 和胃降逆汤加减治疗肝胃郁热型胃食管反流病疗效观察. 北方药学. 2018(11): 131 .
13.	王茜茜，李华岳. 加减乌梅丸方联合穴位针刺对胃食管反流病患者食管动力的影响. 中国中医药现代远程教育. 2018(23): 42-44 .

Other cited types(7)

Get Citation

PDF

XML

Article views PDF downloads Cited by(20)

Turn off MathJax

Article Contents

Abstract

References

Relationships of serum angiopoietin-like protein 4 and fibroblast growth factor 23 levels with severity and prognosis of patients with diabetes nephropathy